Yum! Brands, Inc. (NYSE:YUM) shares decreased -1.36% in last trading session and ended the day at $68.14. YUM Gross Margin is 27.70% and its has a return on assets of 11.20%. Yum! Brands, Inc. (NYSE:YUM) quarterly performance is 1.68%.
Yum! Brands, Inc. (NYSE:YUM) Chairman David Novak will retire in May, ending a three-decade career with the restaurant giant. The Louisville-based company said Tuesday it plans to name one of its board members to succeed Novak at its annual meeting in May.
Symantec Corporation (NASDAQ:SYMC) shares moved down -0.05% in last trading session and ended the day at $20.49. SYMC Gross Margin is 82.40% and its has a return on assets of 5.20%. Symantec Corporation (NASDAQ:SYMC) quarterly performance is -1.88%.
Symantec Corporation (NASDAQ:SYMC) and The Carlyle Group (NASDAQ: CG) announced that they expect to close Carlyle’s acquisition of Veritas on January 29, 2016, subject to the satisfaction of customary closing conditions. The closing was previously expected to take place on January 1, 2016.
Gilead Sciences Inc. (NASDAQ:GILD) caters to the Healthcare space. It has a net profit margin of 53.80% and weekly performance is -4.68%. On the last day of trading company shares ended up at $96.45. Gilead Sciences Inc. (NASDAQ:GILD) distance from 50-day simple moving average (SMA50) is -5.46%.
On 2 January, Gilead Sciences Inc. (NASDAQ:GILD) has grown to be a leading biotech company in the past few years, mostly on the back of the phenomenal success of its hepatitis C franchise. The drug-maker’s two revolutionary HCV drugs, Harvoni and Sovaldi, are two of the fastest-growing medicines in history, boasting cure rates of 8-24 weeks, down from a prior 24-48 week treatment period.
Valero Energy Corporation (NYSE:VLO) shares decreased -5.31% in last trading session and ended the day at $68.26. VLO Gross Margin is 15.00% and its has a return on assets of 10.50%. Valero Energy Corporation (NYSE:VLO) quarterly performance is 4.62%.
Zacks Investment Research upgraded shares of Valero Energy Corporation (NYSE:VLO) from a hold rating to a buy rating in a research note published on Monday,MarketBeat.Com reports. Zacks Investment Research currently has $80.00 price target on the stock.
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) caters to the Healthcare space. Its weekly performance is -22.95%. On the last day of trading company shares ended up at $86.44. Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) distance from 50-day simple moving average (SMA50) is -35.49%.
On 6 January, Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) said that, it provides an overview of the Ultragenyx Pharmaceutical Inc. ’s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Ultragenyx Pharmaceutical Inc., complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases.